Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Disadvantage === As some proteins require chaperonin for proper folding, Komagataella is unable to produce a number of proteins, since it does not contain the appropriate chaperones. The technologies of introducing genes of mammalian chaperonins into the yeast genome and overexpressing existing chaperonins still require improvement.
== Metabolism == Stercobilin results from breakdown of the heme moiety of hemoglobin found in erythrocytes (red blood cells). Macrophages break down senescent erythrocytes and break the heme down into biliverdin, which rapidly reduces to free bilirubin. Bilirubin binds tightly to plasma proteins (especially albumin) in the blood stream and is transported to the liver, where it is conjugated with one or two glucuronic acid residues into bilirubin diglucuronide, and secreted into the small intestine as bile. In the small intestine, some bilirubin glucuronide is converted back to bilirubin via bacterial enzymes in the terminal ileum. This bilirubin is further converted to colorless urobilinogen by the bacterial enzyme bilirubin reductase. Urobilinogen that remains in the colon can either be reduced to stercobilinogen and finally oxidized to stercobilin, or it can be directly reduced to stercobilin. Stercobilin is responsible for the brown color of human feces. Stercobilin is then excreted in the feces.
== History == With the capture of Óscar Orlando Nava Valencia in October 2009 and the death of Ignacio Coronel Villarreal, of the Sinaloa Cartel in 29 July 2010, a power vacuum emerged and the Milenio Cartel (then loyal to the Sinaloa Cartel) broke into smaller factions. The most notable were the Jalisco New Generation Cartel (CJNG) headed by Nemesio Oseguera Cervantes "El Mencho" (who suspected the Sinaloa cartel had betrayed its leaders) and La Resistencia headed by Ramiro Pozos "El Molca" who switched alliances to form a brief alliance with Los Zetas (La Resistencia was founded by Sinaloa to counter Los Zetas), and started a turf war for control of the region. Some members of the Milenio Cartel, then a Sinaloa Cartel branch, who splintered and formed the CJNG were Nemesio Oseguera Cervantes (El Mencho), Érick Valencia Salazar (El 85) and Martín Arzola Ortega (El 53). With this split, a turf war against La Resistencia, headed by Ramiro Pozos (El Molca), and Los Zetas for the control of the region started. Emilio Alejandro Pulido Saldaña, better known as "El Tiburón", was considered to be a co-founder as well.
October 23, denoted 10/23 in the US, is recognized by some as Mole Day. It is an informal holiday in honor of the unit among chemists. The date is derived from the Avogadro number, which is approximately 6.022×1023. It starts at 6:02 a.m. and ends at 6:02 p.m. Alternatively, some chemists celebrate June 2 (06/02), June 22 (6/22), or 6 February (06.02), a reference to the 6.02 or 6.022 part of the constant.
Sources: en.wikipedia.org
Alistair Darling, Baron Darling of Roulanish, 70, British politician, chancellor of the Exchequer (2007–2010), MP (1987–2015) and member of the House of Lords (2015–2020). 1 December – Brigit Forsyth, 83, Scottish actress (Whatever Happened to the Likely Lads?, Boon, Still Open All Hours). 10 December – Willie McCulloch, 75, Scottish football player (Alloa Athletic, Airdrieonians) and manager (Cowdenbeath). (death announced on this date) 14 December – Hanzala Malik, 67, Scottish politician, MSP (2011–2016). (death announced on this date) 19 December – Sir Norman Arthur, 92, British military officer and Olympic equestrian (1960), GOC Scotland (1985–1988) and Lord Lieutenant of Kirkcudbright (1996–2006). (death announced on this date) 27 December – Jack McLean, 78, Scottish journalist and art teacher.
KSM = KSW/ KMW As can be observed from Figure 1, KMW is independent of any effects from the stationary phase, assuming the same micellar mobile phase. The validity of the retention mechanism proposed by Armstrong and Nome has been successfully, and repeated confirmed experimentally. However, some variations and alternate theories have also been proposed. Jandera and Fischer developed equations to describe the dependence of retention behavior on the change in micellar concentrations. They found that the retention of most compounds tested decreased with increasing concentrations of micelles. From this, it can be surmised that the compounds associate with the micelles as they spend less time associated with the stationary phase. Foley proposed a similar retentive model to that of Armstrong and Nome which was a general model for secondary chemical equilibria in liquid chromatography. While this model was developed in a previous reference, and could be used for any secondary chemical equilibria such as acid-base equilibria, and ion-pairing, Foley further refined the model for MLC. When an equilibrant (X), in this case surfactant, is added to the mobile phase, a secondary equilibria is created in which an analyte will exist as free analyte (A), and complexed with the equilibrant (AX). The two forms will be retained by the stationary phase to different extents, thus allowing the retention to be varied by adjusting the concentration of equilibrant (micelles).
Sonography (ultrasound diagnostics) is a versatile and widely used imaging modality in medical diagnostics. Ultrasound is also used in therapy. However, it uses mechanical waves and no ionizing or non-ionizing radiation. Patient safety is ensured if the recommended limits for avoiding cavitation and overheating are observed, see also Safety Aspects of Sonography. Even devices that use alternating magnetic fields in the radiofrequency range, such as magnetic resonance imaging (MRI), do not use ionizing radiation. MRI was developed as an imaging technique in 1973 by Paul Christian Lauterbur (1929-2007) with significant contributions from Sir Peter Mansfield (1933-2017). Jewelry or piercings can become very hot; on the other hand, a high tensile force is exerted on the jewelry, which in the worst case can cause it to be torn out. To avoid pain and injury, jewelry containing ferromagnetic metals should be removed beforehand. Pacemakers, defibrillator systems, and large tattoos in the examination area that contain metallic color pigments may heat up or cause second-degree burns or malfunction of the implants.
Sources: en.wikipedia.org
On 1 July 2016, Townsend joined Premier League club Crystal Palace on a five-year contract from Newcastle following their relegation to the Championship. Palace triggered his £13 million release clause just six months after he joined from Tottenham. He was originally assigned the number 17 shirt for his first season with Palace. However, after Yannick Bolasie left for Everton, Townsend was reassigned the vacant number 10 shirt previously worn by Bolasie. On 13 August 2016, Townsend made his debut in a 1–0 defeat against West Bromwich Albion in the Premier League. He scored his first goal for the club in a 4–1 victory over Stoke City in the league on 18 September. On 22 December 2018, Townsend scored a 30-yard volley in a 3–2 league win against Manchester City. His strike was later voted as Premier League Goal of the Month for December and Premier League Goal of the Season, as well as making the shortlist for the 2019 FIFA Puskás Award. In June 2021, Townsend was announced to be one of the players released by Crystal Palace at the end of the 2020–21 season, ending his five-year tenure with the side.
The main symptom of osteogenesis imperfecta is fragile, low mineral density bones; all types of OI have some bone involvement. In moderate and especially severe OI, the long bones may be bowed, sometimes extremely so. The weakness of the bones causes them to fracture easily—a study at the Endocrine Unit at the National Institute of Child Health in Karachi, Pakistan found an average of 5.8 fractures per year in untreated children. Fractures typically occur much less after puberty, but begin to increase again in women after menopause and in men between the ages of 60 and 80. Joint hypermobility is also a common sign of OI, thought to be because the affected genes are the same as those that cause some types of Ehlers–Danlos syndrome.
=== Modern uses === Today, animal glues are sparsely industrialized, but still used for making and restoring violin family instruments, paintings, illuminated parchment manuscripts, and other artifacts. Gelatin, a form of animal glue, is found in many contemporary products, such as gelatin desserts, marshmallows, pharmaceutical capsules, and photographic film, and is used to reinforce sinew wrappings, wood, leather, bark and paper. Hide glue is also preferred by many luthiers over synthetic glues for its reversibility, creep-resistance and tendency to pull joints closed as it cures. As well as being used as an adhesive, animal glue is used for sizing or varnish, although it is not as frequently used as other adhesives because it is water-soluble. Other aspects, such as the difficulty of storing it in a wet state and the need for fresh raw materials (the animal skin cannot be rotten or grease-burned), make it more difficult to obtain and use. Factories now produce other forms of adhesives, as the process for animal glue is complex. Animal glues will also darken with age and shrink as they dry, giving them the potential to harm wood, paper, or works of art. Too much handling and too many changes in temperature or humidity can cause further harm. Some companies in Canada and other countries still produce animal, hide and hoof glues from horses. Recently, animal glue has been replaced by other adhesives and plastics, but remains popular for restoration.
== Interactions == Methocarbamol may inhibit the effects of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in those with myasthenia gravis taking anticholinesterase medications. Methocarbamol may disrupt certain screening tests as it can cause color interference in laboratory tests for 5-hydroxy-indoleacetic acid (5-HIAA) and in urinary testing for vanillylmandelic acid (VMA) using the Gitlow method.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.